Boston Partners Boosts Holdings in Innoviva, Inc. $INVA

Impact · against what's priced in

Boston Partners' 40.6% increase in its Innoviva position provides a modest positive signal regarding institutional confidence. However, as a trailing 13F filing reflecting a relatively small total stake of 1.39%, it lacks the catalyst strength to drive a significant price movement.

INVA+0.10

No priced-in read yet

In context

Boston Partners increased its position by 252,534 shares to reach a total of 875,084 shares, signaling institutional accumulation of the biotech firm.

Read from the article alone

• biotech
• 13f
• INVA
• biotechnology
• institutional ownership
• stock accumulation

Search tags